JAK inhibitor improves alopecia, with caveats

SCOTTSDALE, ARIZ. – The Janus kinase (JAK) inhibitor tofacitinib dramatically improved several cases of alopecia areata (AA), although some patients relapsed to worse than baseline after completing treatment in a small open label pilot trial. “Regrowth was demonstrated in 11 out of 12 patients on...
Source: Skin and Allergy News - Category: Dermatology Source Type: news